IDH1 and central nervous system cancer: Although IDH1 mutation has dual effects, acting either as an oncogene or as a tumor suppressor gene in glioma [7, 33], patients with IDH mutation exhibited better prognosis than those with wild-type IDH1 [34, 35] (Supplementary Fig. S8).